<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ateroskleroz</journal-id><journal-title-group><journal-title xml:lang="ru">Атеросклероз</journal-title><trans-title-group xml:lang="en"><trans-title>Ateroscleroz</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-256X</issn><issn pub-type="epub">2949-3633</issn><publisher><publisher-name>НИИТПМ-филиал ИЦиГ СО РАН</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15372/ATER20180101</article-id><article-id custom-type="elpub" pub-id-type="custom">ateroskleroz-61</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>КЛИНИЧЕСКАЯ ЗНАЧИМОСТЬ И ДИНАМИКА БИОМАРКЕРОВ РЕМОДЕЛИРОВАНИЯ МИОКАРДА У БОЛЬНЫХ ИНФАРКТОМ МИОКАРДА С ПОДЪЕМОМ СЕГМЕНТА ST И СОХРАНЕННОЙ ФУНКЦИЕЙ ЛЕВОГО ЖЕЛУДОЧКА</article-title><trans-title-group xml:lang="en"><trans-title>Clinical significance and dynamics of biomarkers of myocardial remodeling in patients with ST segment elevation myocardial infarction and preserved left ventricular function</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Печерина</surname><given-names>Т. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Pecherina</surname><given-names>T. B.</given-names></name></name-alternatives><email xlink:type="simple">tb.pechorina@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Федорова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Fedorova</surname><given-names>N. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Герман</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>German</surname><given-names>A. I.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чернобай</surname><given-names>А. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Chernobay</surname><given-names>A. G.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Солодилова</surname><given-names>Т. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Solodilova</surname><given-names>T. P.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каретникова</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Karetnikova</surname><given-names>V. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Груздева</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gruzdeva</surname><given-names>O. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Поликутина</surname><given-names>О. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Polikutina</surname><given-names>O. M.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кашталап</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kashtalap</surname><given-names>V. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Барбараш</surname><given-names>О. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Barbarash</surname><given-names>O. L.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний</institution></aff><aff xml:lang="en"><institution>Federal State Budgetary Research Institution «Scientific-research Institute for Complex Problems of cardiovascular disease»</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>27</day><month>09</month><year>2019</year></pub-date><volume>14</volume><issue>1</issue><fpage>5</fpage><lpage>15</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Печерина Т.Б., Федорова Н.В., Герман А.И., Чернобай А.Г., Солодилова Т.П., Каретникова В.Н., Груздева О.В., Поликутина О.М., Кашталап В.В., Барбараш О.Л., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Печерина Т.Б., Федорова Н.В., Герман А.И., Чернобай А.Г., Солодилова Т.П., Каретникова В.Н., Груздева О.В., Поликутина О.М., Кашталап В.В., Барбараш О.Л.</copyright-holder><copyright-holder xml:lang="en">Pecherina T.B., Fedorova N.V., German A.I., Chernobay A.G., Solodilova T.P., Karetnikova V.N., Gruzdeva O.V., Polikutina O.M., Kashtalap V.V., Barbarash O.L.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://ateroskleroz.elpub.ru/jour/article/view/61">https://ateroskleroz.elpub.ru/jour/article/view/61</self-uri><abstract><p>Цель: определить клиническую значимость маркеров ремоделирования миокарда (NT-proBNP, галектина-3, sST2, ММП-1, 2, 3 и ТИМП-1) у больных инфарктом миокарда с подъемом сегмента ST и сохранной функцией левого желудочка. Материал и методы. В исследование последовательно включены 100 пациентов с диагнозом инфаркт миокарда с подъемом сегмента ST (ИМпST) с фракцией выброса левого желудочка ≥40 %. Всем пациентам проведена реваскуляризация симптомозависимой артерии. Эхокардиографическое исследование проводилось на первые, 10-12-е сутки госпитализации и через год. В эти же сроки оценивали концентрацию в сыворотке крови матриксных металлопротеиназ-1, 2 и 3 (ММП), тканевого ингибитора матриксной металлопротеиназы-1 (ТИМП-1), галектина-3, N-терминального мозгового натрийуретического пропептида (NT-proBNP), стимулирующего фактора роста - растворимого белка семейства рецепторов ИЛ-1 (sST2). Результаты. Концентрация ММП-3, определенная на 10-12-е сутки инфаркта миокарда (ИМ), в 1,62 раза превышала значения, измеренные на первые сутки. В то время как концентрация растворимого ST2-рецептора, напротив, на 10-12-е сутки почти в 2 раза оказалась меньше значений, измеренных на первые сутки. В период госпитализации определена также статистически значимая динамика для маркеров: галектина-3 ( p = 0,0001) и NT-proBNP ( p = 0,0361) - уменьшение к 10-12-м суткам, ММП-2 - увеличение значений к 10-12-м суткам ( p = 0,0003). Анализируя различия в концентрациях изучаемых маркеров с учетом наличия/отсутствия признаков ДД, обращает внимание факт больших медианных значений в группе пациентов с ДД ( n = 38): галектина-3 - в каждой из точек наблюдения, NT-proBNP - на 10-12-е сутки и через год, ММП-1 - на первые и 10-12-е сутки наблюдения, ММП-2 - на годовом этапе наблюдения, ММП-3 - на первые и 10-12-е сутки от ИМ, ТИМП-1 - напротив, в группе пациентов с ДД значения концентраций были ниже в сравнении с пациентами без ДД ( n = 62) как на первые сутки, так и через год. Для sST2 достоверных различий не получено. Выводы. Определены достоверные различия в уровнях изучаемых биомаркеров между группами с учетом наличия/отсутствия диастолической дисфункции у пациентов с сохраненной и средней фракцией выброса левого желудочка.</p></abstract><trans-abstract xml:lang="en"><p>Objective: to determine the clinical significance of markers of myocardial remodeling (NT-proBNP, galectin-3, sST2, MMP-1, 2, 3 and TIMP-1) in patients with ST segment elevation myocardial infarction and preserved left ventricular function. Materials and methods. 100 consecutive patients diagnosed with ST segment elevation myocardial infarction (STEMI) and LV ejection fraction ≥40 % were included. All patients underwent revascularization of the culprit artery. Echocardiography was performed in all the patients on days 1 day, 10-12 and in a year after hospitalization. In all the patients on admission, days 10-12 and in a year after STEMI serum concentrations of the following markers were assessed: matrix metalloproteinases-1, 2 and 3 (MMP), tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), galectin-3; N-terminal brain natriuretic propeptide (NT-proBNP); soluble protein of the IL-1 receptor family (sST2). Results. The concentration of MMP-3, determined on days 10-12 of the MI, was 1.62 times higher than the values measured on the first day. While the concentration of soluble ST2 receptor, on the contrary, is almost twice as low on days 10-12 as measured on the 1st day. Also statistically significant dynamics in the period of hospitalization was determined for galectin-3 ( p = 0.0001), MMP-2 ( p = 0.0003), NT-proBNP ( p = 0.0361). Analyzing the differences in the concentrations of the markers under study, taking into account the presence / absence of signs of DD, draws attention to the fact of large median values in the group of patients with DD ( n = 38): galectin-3 at each of the observation points, NT-proBNP by the 10-12th day and in a year, MMP-1 - on the 1st and 10-12th day of observation, MMP-2 - at the annual observation stage, MMP-3 - on the 1st and 10-12th days from the MI, TIMP-1 - on the contrary, in the group of patients with DD the concentrations were lower in comparison with patients without DD ( n = 62) both on the 1st day and a year later. For sST2 no significant differences were found. Conclusions. It was determined that in the group of patients with ST segment elevation myocardial infarction and preserved LV function in the hospital period and a year later, a statistically significant dynamics of the majority of studied markers was registered, which indicates the regular processes of structural and functional remodeling of myocardium of the LV at different stages of observation. Significant differences in the levels of studied markers were determined between the groups, taking into account the presence / absence of diastolic dysfunction in patients with preserved and middle fraction of LV ejection.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>биологические маркеры</kwd><kwd>инфаркт миокарда</kwd><kwd>сохранная функция левого желудочка</kwd><kwd>диастолическая дисфункция</kwd></kwd-group><kwd-group xml:lang="en"><kwd>biological markers</kwd><kwd>myocardial infarction</kwd><kwd>preserved left ventricular function</kwd><kwd>diastolic dysfunction</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Lloyd-Jones D., Adams R., Carnethon M. et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee // Circulation. 2009 Jan 27. Vol. 119, N 3. P. 21-181.</mixed-citation><mixed-citation xml:lang="en">Lloyd-Jones D., Adams R., Carnethon M. et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee // Circulation. 2009 Jan 27. Vol. 119, N 3. P. 21-181.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Roger V.L., Weston S.A., Redfield M.M. et al. Trends in heart failure incidence and survival in a community-based population // JAMA. 2004 Jul 21. Vol. 292, N 3. P. 344-350.</mixed-citation><mixed-citation xml:lang="en">Roger V.L., Weston S.A., Redfield M.M. et al. Trends in heart failure incidence and survival in a community-based population // JAMA. 2004 Jul 21. Vol. 292, N 3. P. 344-350.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Рекомендации ESC по диагностике и лечению острой и хронической сердечной недостаточности 2016 // Рос. кардиол. журн. 2017. Т. 1 (141). С. 7-81. http://dx.doi.org/10.15829/1560-4071-2017-1-7-81</mixed-citation><mixed-citation xml:lang="en">Рекомендации ESC по диагностике и лечению острой и хронической сердечной недостаточности 2016 // Рос. кардиол. журн. 2017. Т. 1 (141). С. 7-81. http://dx.doi.org/10.15829/1560-4071-2017-1-7-81</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Gazewood J.D., Turner P.L. Heart Failure with Preserved Ejection Fraction: Diagnosis and Management // Am. Fam. Phys. 2017. Nov 1. Vol. 96, N 9. P. 582-588.</mixed-citation><mixed-citation xml:lang="en">Gazewood J.D., Turner P.L. Heart Failure with Preserved Ejection Fraction: Diagnosis and Management // Am. Fam. Phys. 2017. Nov 1. Vol. 96, N 9. P. 582-588.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Tromp J., Mohsin A.F.K., IJsbrand T.K. et al. Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction // J. Am. Heart Associat. 2017. N 6. P. e003989</mixed-citation><mixed-citation xml:lang="en">Tromp J., Mohsin A.F.K., IJsbrand T.K. et al. Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction // J. Am. Heart Associat. 2017. N 6. P. e003989</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Havmöller R., Chugh S.S. Plasma biomarkers for prediction of sudden cardiac death: another piece of the risk stratification puzzle? // Circ. Arrhythm. Electrophys. 2012 Feb. Vol. 5, N 1. P. 237-243.</mixed-citation><mixed-citation xml:lang="en">Havmöller R., Chugh S.S. Plasma biomarkers for prediction of sudden cardiac death: another piece of the risk stratification puzzle? // Circ. Arrhythm. Electrophys. 2012 Feb. Vol. 5, N 1. P. 237-243.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Van Kimmenade R.R., Januzzi J.L.Jr. Emerging biomarkers in heart failure // Clin. Chem. 2012 Jan. Vol. 58, N 1. P. 127-138.</mixed-citation><mixed-citation xml:lang="en">Van Kimmenade R.R., Januzzi J.L.Jr. Emerging biomarkers in heart failure // Clin. Chem. 2012 Jan. Vol. 58, N 1. P. 127-138.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmad T., Fiuzat M., Neely B. et. al. Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients with Chronic Heart Failure // JACC Heart Fail. 2014 Jun. Vol. 2, N 3. P. 260-268.</mixed-citation><mixed-citation xml:lang="en">Ahmad T., Fiuzat M., Neely B. et. al. Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients with Chronic Heart Failure // JACC Heart Fail. 2014 Jun. Vol. 2, N 3. P. 260-268.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Xie P., Cao Y.S., Su P. et al. Expression of toll-like receptor 4, tumor necrosis factor- alpha, matrix metalloproteinase-9 and effects of benazepril in patients with acute coronary syndromes // Clin. Med. Insights Cardiol. 2010. Vol. 4. P. 89-93.</mixed-citation><mixed-citation xml:lang="en">Xie P., Cao Y.S., Su P. et al. Expression of toll-like receptor 4, tumor necrosis factor- alpha, matrix metalloproteinase-9 and effects of benazepril in patients with acute coronary syndromes // Clin. Med. Insights Cardiol. 2010. Vol. 4. P. 89-93.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure // Eur. Heart J. 2016. Vol. 37. P. 2129-2200.</mixed-citation><mixed-citation xml:lang="en">2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure // Eur. Heart J. 2016. Vol. 37. P. 2129-2200.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Huttin O., Coiro S., Selton-Suty Ch. et. al. Prediction of Left Ventricular Remodeling after a Myocardial Infarction: Role of Myocardial Deformation: A Systematic Review and Meta-Analysis // PLoS One. 2016. Vol. 11, N 12: e0168349.</mixed-citation><mixed-citation xml:lang="en">Huttin O., Coiro S., Selton-Suty Ch. et. al. Prediction of Left Ventricular Remodeling after a Myocardial Infarction: Role of Myocardial Deformation: A Systematic Review and Meta-Analysis // PLoS One. 2016. Vol. 11, N 12: e0168349.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Huang D., Cheng J.W.M. Pharmacologic Management of Heart Failure with Preserved Ejection Fraction // The Annals of Pharmacotherapy. 2010. Vol. 44, N 12. P. 1933-1945.</mixed-citation><mixed-citation xml:lang="en">Huang D., Cheng J.W.M. Pharmacologic Management of Heart Failure with Preserved Ejection Fraction // The Annals of Pharmacotherapy. 2010. Vol. 44, N 12. P. 1933-1945.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) - Developed with the special contribution of the Heart Failure Association (HFA) of the ESC // Eur. Heart J. 2016. Vol. 37. P. 2129-2200.</mixed-citation><mixed-citation xml:lang="en">Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) - Developed with the special contribution of the Heart Failure Association (HFA) of the ESC // Eur. Heart J. 2016. Vol. 37. P. 2129-2200.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Sunil Nadar. New Classification for Heart Failure with Mildly Reduced Ejection Fraction // Sultan Qaboos Univ. Med. J. 2017 Feb. Vol. 17, N 1. P. 23-26.</mixed-citation><mixed-citation xml:lang="en">Sunil Nadar. New Classification for Heart Failure with Mildly Reduced Ejection Fraction // Sultan Qaboos Univ. Med. J. 2017 Feb. Vol. 17, N 1. P. 23-26.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Meijers W.C., van der Velde A.R., de Boer R.A. Biomarkers in heart failure with preserved ejection fraction // Neth Heart J. 2016 Apr. Vol. 24, N 4. P. 252-258.</mixed-citation><mixed-citation xml:lang="en">Meijers W.C., van der Velde A.R., de Boer R.A. Biomarkers in heart failure with preserved ejection fraction // Neth Heart J. 2016 Apr. Vol. 24, N 4. P. 252-258.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Martinez-Rumayor A., Richards A.M., Burnett J.C., Januzzi J.L. Jr. Biology of the natriuretic peptides // Am. J. Cardiol. 2008 Feb 4. Vol. 101, N 3A. P. 3-8.</mixed-citation><mixed-citation xml:lang="en">Martinez-Rumayor A., Richards A.M., Burnett J.C., Januzzi J.L. Jr. Biology of the natriuretic peptides // Am. J. Cardiol. 2008 Feb 4. Vol. 101, N 3A. P. 3-8.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Lubien E., DeMaria A., Krishnaswamy P. et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings // Circulation. 2002. Vol. 105. P. 595-601.</mixed-citation><mixed-citation xml:lang="en">Lubien E., DeMaria A., Krishnaswamy P. et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings // Circulation. 2002. Vol. 105. P. 595-601.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Maisel A.S., McCord J., Nowak R.M. et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study // J. Am. Coll. Cardiol. 2003. Vol. 41. P. 2010-2017.</mixed-citation><mixed-citation xml:lang="en">Maisel A.S., McCord J., Nowak R.M. et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study // J. Am. Coll. Cardiol. 2003. Vol. 41. P. 2010-2017.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Mak G.S, DeMaria A., Clopton P., Maisel A.S. Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function: comparison with tissue Doppler imaging recordings // Am. Heart J. Vol. 2004, N 148. P. 895-902.</mixed-citation><mixed-citation xml:lang="en">Mak G.S, DeMaria A., Clopton P., Maisel A.S. Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function: comparison with tissue Doppler imaging recordings // Am. Heart J. Vol. 2004, N 148. P. 895-902.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tschope C., Kasner M., Westermann D. et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements // Eur. Heart J. 2005. Vol. 26. P. 2277-2284.</mixed-citation><mixed-citation xml:lang="en">Tschope C., Kasner M., Westermann D. et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements // Eur. Heart J. 2005. Vol. 26. P. 2277-2284.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Iwanaga Y., Nishi I., Furuichi S. et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure // J. Am. Coll. Cardiol. 2006. Vol. 47. P. 742-748.</mixed-citation><mixed-citation xml:lang="en">Iwanaga Y., Nishi I., Furuichi S. et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure // J. Am. Coll. Cardiol. 2006. Vol. 47. P. 742-748.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Yancy C.W., Jessup M., Bozkurt B. et al. ACCF/AHA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines // Circulation. 2013. Vol. 128: e240-e327.</mixed-citation><mixed-citation xml:lang="en">Yancy C.W., Jessup M., Bozkurt B. et al. ACCF/AHA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines // Circulation. 2013. Vol. 128: e240-e327.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">de Boer R.A., Lok D.J., Jaarsma T. et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction // Ann. Med. 2011. Vol. 43. P. 60-68.</mixed-citation><mixed-citation xml:lang="en">de Boer R.A., Lok D.J., Jaarsma T. et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction // Ann. Med. 2011. Vol. 43. P. 60-68.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Carrasco-Sanchez F.J., Aramburu-Bodas O., Salamanca-Bautista P. et al. Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction // Int. J. Cardiol. 2013. Vol. 169. P. 177-182.</mixed-citation><mixed-citation xml:lang="en">Carrasco-Sanchez F.J., Aramburu-Bodas O., Salamanca-Bautista P. et al. Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction // Int. J. Cardiol. 2013. Vol. 169. P. 177-182.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Edelmann F., Wachter R., Schmidt A.G. et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial // JAMA. 2013. Vol. 309. P. 781-791.</mixed-citation><mixed-citation xml:lang="en">Edelmann F., Wachter R., Schmidt A.G. et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial // JAMA. 2013. Vol. 309. P. 781-791.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Edelmann F., Holzendorf V., Wachter R. et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial // Eur. J. Heart Fail. 2015. Vol. 17. P. 214-223.</mixed-citation><mixed-citation xml:lang="en">Edelmann F., Holzendorf V., Wachter R. et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial // Eur. J. Heart Fail. 2015. Vol. 17. P. 214-223.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Bayes-Genis A., Pascual-Figal D., Januzzi J.L. et. al. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure // Rev. Esp. Cardiol. Vol. 63, N 10. P. 1171-1178.</mixed-citation><mixed-citation xml:lang="en">Bayes-Genis A., Pascual-Figal D., Januzzi J.L. et. al. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure // Rev. Esp. Cardiol. Vol. 63, N 10. P. 1171-1178.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Frioes F., Lourenco P., Laszczynska O. et al. Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction // Clin. Res. Cardiol. 2015. Vol. 104. P. 491-499.</mixed-citation><mixed-citation xml:lang="en">Frioes F., Lourenco P., Laszczynska O. et al. Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction // Clin. Res. Cardiol. 2015. Vol. 104. P. 491-499.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Manzano-Fernandez S., Mueller T., Pascual-Figal D. et. al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction // Am. J. Cardiol. 2011. Vol. 107. P. 259-267.</mixed-citation><mixed-citation xml:lang="en">Manzano-Fernandez S., Mueller T., Pascual-Figal D. et. al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction // Am. J. Cardiol. 2011. Vol. 107. P. 259-267.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson J.L. Matrix metalloproteinases and their inhibitors in cardiovascular pathologies: current knowledge and clinical potential. Metalloproteinases // In Medicine. 2014. Vol. 1. P. 21-36.</mixed-citation><mixed-citation xml:lang="en">Johnson J.L. Matrix metalloproteinases and their inhibitors in cardiovascular pathologies: current knowledge and clinical potential. Metalloproteinases // In Medicine. 2014. Vol. 1. P. 21-36.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
